Effective drug combinations in breast, colon and pancreatic cancer cells
2022 · Nature · 440 citations
https://doi.org/10.1038/s41586-022-04437-2
E
Elizabeth A. Coker
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
191
Papers
1.6K
Citations
14
h-index
15
i10-index
Elizabeth A. Coker is an academic researcher from AstraZeneca (Brazil). The author has contributed to research in topics: Computational Drug Discovery Methods & Melanoma and MAPK Pathways & Mathematical Biology Tumor Growth. The author has an h-index of 14, co-authored 163 publications.
ORCID: 0000-0003-4934-8887Papers by this author
worksAKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
2022 · Oncogene · 30 citations
https://doi.org/10.1038/s41388-022-02482-9
Validation_screen_All_tissues_raw_data.csv.zip
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.19141922
Validation_screen_All_tissues_day1_data.csv.zip
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.19141928
Significant ANOVA hits
2023 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.22362871
SiGNet: a signaling network data simulator to enable signaling network inference
2017 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.4578808
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat